Sirtex profit grows 30% in FY14
Sirtex Medical (ASX:SRX) grew its net profit for the financial year ending in June by 30.6% to $23.9 million, thanks to higher sales of its SIR-Spheres liver cancer treatment microspheres.
Sales revenue grew 33.7% to a record $129.4 million, with dose sales increasing to 8561 - another company record.
SIR-Spheres deliver targeted radiation therapy to liver cancers. The product is on sale in the Americas, EMEA and Asia-Pacific.
Revenue from the Americas grew 37.4% to $96 million, thanks to a 22.5% increase in dose sales. EMEA sales were up 24.6% to $27.7 million, but dose sales increased a slimmer 5.6%. APAC revenue increased 20.9% to $5.7 million and dose sales grew 12.4% to 809 units.
Sirtex CEO said the company had delivered “another solid result” during the financial year. “We believe our current growth rate is sustainable. However, a positive result from our clinical studies should see an acceleration or step change in our growth.”
The company is currently engaged in the multi-year Sirflox marketing study and expects the results from the trial to help convince more clinicians to take up SIR-Spheres as a first-line treatment for liver cancer.
The study completed recruitment in April 2013, and results are expected to be released in 2015.
Sirtex Medical (ASX:SRX) shares were trading 0.2% lower at $20.00 as of around 2 pm on Wednesday.
'Longevity gene' could reverse damage from rapid aging disease
A gene found in supercentenarians, who live exceptionally long lives, could counteract the...
How a common gene mutation increases liver disease risk
Liver damage can be caused in people after exposure to high levels of acrolein, especially in...
Gene therapy slows Huntington's disease progression in trial
Patients receiving the treatment were found to experience 75% less progression of the disease...
